Alexion To Pay $10M To Settle Patent Lawsuit
Under the settlement, Alexion will pay $10 million in order to acquire all rights and interests to the patents at issue, making payments over the remainder of 2008 and 2009. The ongoing litigation will be dismissed.
Alexion's Soliris drug was approved by the FDA to treat a rare blood disorder, paroxysmal nocturnal humoglobinuria, or PNH, which strikes one in a million...
To view the full article, register now.